Harnessing Functional Genomics to Reverse Chemoresistance in Breast Cancer
| Autor: | Brian Bodemann |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
biology
medicine.drug_class medicine.medical_treatment medicine.disease Monoclonal antibody Bioinformatics Targeted therapy Breast cancer Breast cancer cell line Trastuzumab medicine biology.protein Cancer research Human genome Antibody skin and connective tissue diseases Functional genomics medicine.drug |
| DOI: | 10.21236/ada484470 |
| Popis: | Targeted therapy has proven to be an effective strategy in the treatment of breast cancer. An example of successful targeted therapy is trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of HER2, a receptor which is overexpressed in many breast cancers. The goal of my project is to identify molecular targets for conjunctive therapy that will increase efficacy of trastuzumab therapy. To identify molecular targets necessary for breast cancer cell survival in the presence of trastuzumab, a breast cancer cell line with known cytostatic sensitivity to trastuzumab, will be screened using a high throughput assay with a unique small interfering (si)RNA library targeting all 21,125 known genes in the human genome database. This information will help identify new synergistic combinations with existing drugs and novel therapeutic targets that can act synergistically as initial therapy and upon the development of resistance. During the time covered by this annual summary, I have made major progress towards fulfilling my training requirements and finished optimizing conditions for the execution of this screen as outlined in AIM1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|